Summary Dystrophin (DMD) - Dystrophin is a cytoplasmic protein. It anchors the extracellular matrix to the cytoskeleton via F-actin. It acts as ligand for dystroglycan. It act as component of the dystrophin-associated glycoprotein complex which accumulates at the neuromuscular junction and at a variety of synapses in the peripheral and central nervous systems and has a structural function in stabilizing the sarcolemma.
Dystrophin (DMD) pipeline Target constitutes close to 48 molecules. Out of which approximately 44 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 4, 1, 23 and 12 respectively. Similarly, the universities portfolio in Preclinical stages comprises 4 molecules, respectively. Report covers products from therapy areas Genetic Disorders and Musculoskeletal Disorders which include indications Duchenne Muscular Dystrophy and Muscular Dystrophy.
The latest report Dystrophin (DMD) - Pipeline Review, H2 2019, outlays comprehensive information on the Dystrophin (DMD) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Dystrophin (DMD) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Scope - The report provides a snapshot of the global therapeutic landscape for Dystrophin (DMD) - The report reviews Dystrophin (DMD) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Dystrophin (DMD) targeted therapeutics and enlists all their major and minor projects - The report assesses Dystrophin (DMD) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Dystrophin (DMD) targeted therapeutics
Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Dystrophin (DMD) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Dystrophin (DMD) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Our reports have been used by over 10K customers, including:
N Sulphoglucosamine Sulphohydrolase - Pipeline Review, H2 2019 Summary N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 126.96.36.199) pipeline Target constitutes close to 8 molecules. The latest report N Sulphoglucosamine Sulphohydrolase - Pipeline Review,...
Neuropeptide Y Receptor Type 2 - Pipeline Review, H2 2019 Summary Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Neuropeptide Y receptor type 2 (Y2R) is a protein encoded by the NPY2R gene. It is expressed abundantly in the central nervous system. It is also seen in the spleen, liver...
Huntingtin - Pipeline Review, H2 2019 Summary Huntingtin (Huntington Disease Protein or HTT) pipeline Target constitutes close to 19 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The latest report Huntingtin - Pipeline...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.